CURVEBEAM AI LIMITED (CVB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CVB - CURVEBEAM AI LIMITED

FNArena Sector : Medical Equipment & Devices

Year End: June

GICS Industry Group : NONE

Debt/EBITDA: -0.75

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.115 25 Mar 2025	0.000 OPEN $0.12	0.000 HIGH $0.12	100,028 LOW $0.12

TARGET

$0.18

56.5% upside

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .

FNARENA'S MARKET CONSENSUS FORECASTS

Title	FY23 Actual	FY24 Actual	FY25 Forecast	FY26 Forecast
EPS (cps)	xxx	- 7.9	- 17.4	xxx
DPS (cps)	xxx	0.0	0.0	xxx
EPS Growth	xxx	N/A	N/A	xxx
DPS Growth	xxx	N/A	N/A	xxx
PE Ratio	xxx	N/A	N/A	xxx
Dividend Yield	xxx	N/A	0.0%	xxx
Div Pay Ratio(%)	xxx	N/A	N/A	xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2023	2024
EPS Basic	xxx	-7.9
DPS All	xxx	0.0
Sales/Revenue	xxx	6.5 M
Book Value Per Share	xxx	11.8
Net Operating Cash Flow	xxx	-21.9 M
Net Profit Margin	xxx	-353.94 %

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2023	2024
Return on Capital Employed	xxx	-
Return on Invested Capital	xxx	-60.78 %
Return on Assets	xxx	-37.05 %
Return on Equity	xxx	-
Return on Total Capital	xxx	-60.80 %
Free Cash Flow ex dividends	xxx	-21.9 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2023	2024
Short-Term Debt	xxx	1 M
Long Term Debt	xxx	15 M
Total Debt	xxx	16 M
Goodwill - Gross	xxx	20 M
Cash & Equivalents - Generic	xxx	6 M
Price To Book Value	xxx	1.31

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Negative
Growth
Slowing

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2023	2024
Capex	xxx	0.3 M
Capex % of Sales	xxx	4.96 %
Cost of Goods Sold	xxx	22 M
Selling, General & Admin. Exp & Other	xxx	9 M
Research & Development	xxx	1 M
Investments - Total	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Negative
Growth
Slowing

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Bell Potter	03/03/2025	1	Speculative Buy	$0.18	56.52%	Bell Potter details Curvebeam AI's 1H25 revenue rose 39%, with gross profit of $2.2m. Seven devices were delivered, fulfilling most of the ten outstanding purchase orders as of June 2024, the broker explains. Adjusted earnings (EBITDA) loss was -$7.0m, lower than the prior year but in line with 2H24, the analyst highlights, and cash burn was -$7.5m, leaving closing cash at $8.8m. The company has 14 outstanding purchase orders, with at least ten expected to be fulfilled in 2H25. Bell Potter expects Curvebeam to have sufficient cash for the short term. Target price lowered to 18c from 26c. Buy (Speculative) rating retained, with Bell Potter citing HiRise validation as a potential long-term value driver. FORECAST Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.40 cents. Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.90 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Bell Potter

03/03/2025

Speculative Buy

$0.18

56.52%

Bell Potter details Curvebeam AI's 1H25 revenue rose 39%, with gross profit of $2.2m.

Seven devices were delivered, fulfilling most of the ten outstanding purchase orders as of June 2024, the broker explains.

Adjusted earnings (EBITDA) loss was -$7.0m, lower than the prior year but in line with 2H24, the analyst highlights, and cash burn was -$7.5m, leaving closing cash at $8.8m.

The company has 14 outstanding purchase orders, with at least ten expected to be fulfilled in 2H25. Bell Potter expects Curvebeam to have sufficient cash for the short term.

Target price lowered to 18c from 26c. Buy (Speculative) rating retained, with Bell Potter citing HiRise validation as a potential long-term value driver.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.90 cents.

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
No data available in table

Access Extra Coverage Research History >

CVB STOCK CHART

FNArena News on CVB

1	FNArena Corporate Results Monitor – 03-03-2025 Mar 03 2025 - Australia

2	FNArena Corporate Results Monitor – 06-09-2024 Sep 06 2024 - Australia

Latest Medical Equipment & Devices News

1	Trend Remains Up For Catapult International Feb 18 2025 - Technicals

2	ESG Focus: Top ASX Companies, Superbugs & Hydrogen Feb 07 2025 - ESG Focus

3	ResMed Shakes Off GLP-1 Scare Feb 04 2025 - Australia

4	ResMed: Another Positive Quarterly Surprise? Jan 30 2025 - Australia

5	The Trend Remains Pro Medicus’ Friend Jan 16 2025 - Technicals

6	Diagnostic Imaging Radiates Opportunity Dec 18 2024 - Small Caps

7	ResMed’s Bounce-Back Complete Oct 29 2024 - Australia

8	Dr Boreham’s Crucible: Pro Medicus Sep 04 2024 - Australia

9	Pro Medicus: Don’t Stop Me Now Aug 20 2024 - Technicals

10	Dr Boreham’s Crucible: Blinklab May 20 2024 - Small Caps

Dividend Yield Today On Last Actual Payout :	0.00
Estimated Dividend Growth (Average Of Past Three Years)
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

Get 2 Weeks free trial

Sign Up

Member Login

CURVEBEAM AI LIMITED (CVB)
Share Price Analysis and Chart